Fig. 1From: Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19–9Flow diagram showing patient enrollment process. FDG, fluorodeoxyglucose; PET, positron emission tomography; NAT, neoadjuvant therapy; PDAC, pancreatic ductal adenocarcinoma; CA 19–9, carbohydrate antigen 19–9Back to article page